Skip to content

CAS 167933-07-5 Flibanserin

Filbanserin is an agonist of serotonin-5HT1A receptor and an antagonist of the 5-HT2A receptor. Binds dopamine receptors with Ki values ranging from 4-24 nM. Used to treat hypoactive sexual desire disorder in females.

Contact me:



Wickrme: rosieeeliu


SKU: AB-167933-07-5 Category: Tags: ,

Flibanserin Description

Product Name:Flibanserin
Synonyms:1,3-Dihydro-1-[2-[4-[3-(trifluoromethyl)phenyl]-1-piperazinyl]ethyl]-2H-benzimidazol-2-one; Addyi; BIMT 17; BIMT 17BS;
CAS NO:167933-07-5
Molecular Formula:C₂₀H₂₁FNO
Molecular Weight:390.4
Density:1.292±0.06 g/cm3(Predicted)
Appearance:white to beige powder
Storage:2-8°C Refrigerator
Solubility:DMSO: soluble10mg/mL, clear

Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. It was originally developed as an antidepressant medication by Boehringer Ingelheim, but showed a lack of efficacy in trials and was further developed as a hypoactive sexual disorder drug by Sprout Pharmaceuticals. Flibanserin’s mechanism of action is attributed to its high affinity for 5-HTA1 and 5-HTA2 receptors, displaying agonist activity on 5-HTA1 and antagonist on 5-HTA2, resulting in lowering of serotonin in the brain as well as an effect on increasing norepinephrine and dopamine neurotransmitters. Flibanserin has a high affinity for serotonin receptors in the brain: it acts as an agonist on 5-HT1A and an antagonist on 5-HT2A. In vivo, flibanserin binds equally to 5-HT1A and 5-HT2A receptors. However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT2A receptors in higher proportion than 5-HT(1A) receptors. It may also moderately antagonize D4 (dopamine) receptors and 5-HT2B and 5-HTB2C. Its action on neurotransmitter receptors may contribute to a reduction in serotonin levels and an increase in dopamine and norepinephrine levels, all of which may play part in reward processing. Flibanserin is sold under the trade name Addyi and is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty.

Click here to know more about Flibanserin!

Welcome to see my personal blog!


There are no reviews yet.

Be the first to review “CAS 167933-07-5 Flibanserin”

Your email address will not be published. Required fields are marked *

You may also like…